background
human
rhinovirus
hrv
common
caus
upper
respiratori
tract
infect
urti
hematolog
malign
hm
patient
predictor
lower
respiratori
tract
infect
lrti
includ
impact
hrv
speci
type
poorli
understood
object
studi
aim
describ
clinic
molecular
epidemiolog
hrv
infect
among
hm
patient
studi
design
april
hrvposit
respiratori
specimen
symptomat
hm
patient
molecularli
character
analysi
partial
viral
protein
gene
sequenc
hrv
lrti
riskfactor
outcom
analyz
use
multivari
logist
regress
result
one
hundr
ten
hm
patient
present
hrv
urti
n
hrv
lrti
n
hypoalbuminemia
ci
p
independ
associ
lrti
clinic
laboratori
marker
host
immun
differ
patient
urti
versu
lrti
detect
bacteri
copathogen
common
lrti
case
among
typeabl
respiratori
specimen
hrva
hrvb
hrvc
one
enteroviru
lrti
rate
among
hrva
hrvb
hrvc
similar
hrva
infect
occur
yearround
hrvb
hrvc
infect
cluster
late
fall
winter
conclus
hrv
associ
lrti
hm
patient
ill
sever
attribut
specif
hrv
speci
type
frequent
detect
bacteri
copathogen
hrv
lrti
substanti
hypothesi
hrv
predispos
bacteri
superinfect
lower
airway
similar
communityacquir
respiratori
virus
human
rhinovirus
hrv
tradit
consid
common
cold
virus
also
play
substanti
role
lower
respiratori
tract
infect
lrti
children
elderli
immunocompromis
host
hrv
classifi
taxonom
within
enteroviru
ev
group
subdivid
three
speci
b
c
across
three
speci
differ
serotyp
sinc
identif
design
hrvc
speci
sever
studi
demonstr
increas
rate
asthma
exacerb
lrti
among
children
hrvc
versu
hrva
hrvb
infect
howev
recent
data
fail
observ
associ
hrv
speci
ill
sever
patient
hematolog
malign
hm
risk
complic
respiratori
viral
infect
includ
prolong
ill
progress
lrti
bacteri
superinfect
understand
predictor
outcom
hrv
lrti
hm
patient
includ
effect
hrv
speci
type
may
aid
riskstratif
empir
antibiot
use
patient
acut
respiratori
ill
studi
aim
describ
clinic
molecular
epidemiolog
hrv
infect
among
hm
patient
engag
care
new
york
citi
nyc
hospit
period
new
yorkpresbyterianweil
cornel
medic
center
nypwcmc
symptomat
hm
patient
test
molecular
method
respiratori
virus
via
nasopharyng
np
swab
bronchoalveolar
lavag
bal
april
march
review
nypwcmc
clinic
microbiolog
laboratori
record
daili
identifi
adult
hm
patient
age
year
test
posit
hrv
exclud
patient
hm
remiss
receiv
chemotherapi
previou
year
hematopoiet
stem
cell
transplant
hsct
recipi
includ
transplant
occur
within
previou
month
andor
chronic
graftversushost
diseas
present
hrvposit
respiratori
specimen
frozen
ship
wadsworth
center
new
york
state
depart
health
albani
ny
molecular
character
clinic
data
correspond
episod
hrv
infect
abstract
electron
medic
record
studi
nypwcmc
clinic
microbiolog
laboratori
perform
molecular
test
respiratori
virus
multiplex
realtim
pcr
filmarray
respiratori
panel
rp
biofir
diagnost
inc
salt
lake
citi
ut
three
hrv
four
ev
speci
detect
rp
due
sequenc
homolog
rp
assay
reliabl
distinguish
hrv
ev
purpos
studi
patient
test
posit
hrvev
target
rp
assay
assum
hrv
infect
confirm
molecular
test
wadsworth
addit
rp
follow
diagnost
microbiolog
studi
perform
bal
fluid
immunocompromis
patient
nypwcmc
use
standard
procedur
gram
stain
bacteri
cultur
calcofluor
white
potassium
hydroxid
stain
fungal
cultur
acidfast
bacillu
stain
mycobacteri
cultur
pcr
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
legionella
direct
fluoresc
antibodi
dfa
cultur
pneumocysti
jirovecii
dfa
aspergillu
galactomannan
aliquot
l
respiratori
sampl
extract
elut
l
easymag
durham
nc
revers
transcript
perform
l
rna
use
quanta
cdna
kit
random
primer
quanta
gaithersburg
md
viral
protein
gene
sequenc
hrv
initi
target
use
pcr
primer
design
center
diseas
control
prevent
cdc
unpublish
kindli
provid
dr
dean
erdman
assay
fail
produc
band
sequenc
assay
primer
target
differ
region
gene
use
gene
assay
fail
gene
sequenc
amplifi
primer
describ
coira
et
al
pcr
product
visual
tae
gel
purifi
use
affimetrix
exozapit
sampl
display
appropri
size
product
affimetrix
santa
clara
ca
sequenc
perform
use
pcr
primer
assay
sequenc
either
gene
first
blast
analyz
determin
hrv
type
sequenc
obtain
use
cdc
unpublish
assay
align
repres
sequenc
speci
b
c
import
genbank
use
clustal
w
multipl
align
program
mega
maximum
likelihood
phylogenet
tree
construct
use
mega
neighborjoin
method
hrva
b
hrvc
sinc
sequenc
obtain
use
nix
et
al
assay
coira
et
al
assay
target
differ
region
use
phylogenet
analysi
urti
defin
rhinorrhea
pharyng
cough
without
clinic
radiograph
evid
lower
respiratori
involv
hypoxia
lrti
defin
cough
dyspnea
sputum
product
fever
hypoxia
new
radiograph
pulmonari
infiltr
lrti
subclassifi
proven
hrv
lrti
hrv
detect
bal
fluid
possibl
hrv
lrti
bronchoscopi
perform
hrv
detect
np
swab
separ
urti
lrti
episod
requir
least
twoweek
symptomfre
period
episod
given
conflict
literatur
effect
hrv
speci
ill
sever
sought
statist
power
detect
differ
lrti
rate
hrvahrvb
versu
hrvc
one
truli
exist
hypothes
hrvc
associ
lrti
often
hrva
hrvb
base
preval
studi
geograph
locat
estim
ratio
hrva
hrvb
versu
hrvc
infect
predict
hm
patient
would
hrv
lrti
estim
absolut
differ
lrti
rate
hrvab
hrvc
infect
therefor
sampl
size
subject
need
group
detect
differ
rate
lrti
level
signific
power
recogn
hrv
ill
sever
may
also
driven
host
geograph
tempor
event
evalu
factor
associ
hrv
lrti
exclud
patient
coinfect
respiratori
pathogen
analysi
patient
lrti
like
undergo
thorough
microbiolog
evalu
potenti
confound
univari
analysi
conduct
use
chisquar
fisher
exact
test
appropri
categor
variabl
pvalu
consid
signific
variabl
pvalu
univari
analysi
subsequ
analyz
multivari
logist
regress
patient
follow
six
month
first
hrv
infect
data
analyz
use
stata
colleg
station
tx
patient
diagnos
hrv
routin
acut
outpati
visit
inpati
admiss
chemotherapi
hsct
fever
andor
respiratori
symptom
acut
reason
fortynin
patient
includ
patient
acut
graftversushost
diseas
gvhd
grade
andor
chronic
gvhd
c
includ
chronic
obstruct
pulmonari
diseaseasthma
n
environment
hypersensit
pneumon
n
radiat
pneumon
n
desquam
interstiti
pneumon
n
bronchiectasi
n
gvhd
lung
n
defin
tobacco
use
within
previou
month
hsct
recipi
acut
leukemia
myelodysplast
syndrom
seventythre
patient
receiv
chemotherapi
corticosteroid
immunosuppress
medic
previou
day
addit
patient
characterist
outlin
tabl
hrv
diagnosi
patient
clinic
diagnosi
urti
patient
possibl
hrv
lrti
patient
proven
hrv
lrti
among
patient
hrv
urti
eight
viral
coinfect
case
bacteri
fungal
coinfect
among
patient
hrv
lrti
bacteri
coinfect
occur
eight
viral
fungal
coinfect
occur
two
patient
tabl
tabl
illustr
clinic
laboratori
variabl
associ
hrv
lrti
patient
without
respiratori
copathogen
signific
differ
put
risk
factor
proven
possibl
hrv
lrti
case
combin
analysi
univari
analysi
inpati
statu
hypoalbuminemia
associ
hrv
lrti
multivari
analysi
hypoalbuminemia
ci
p
remain
independ
associ
hrv
lrti
blast
analysi
determin
genotyp
hrvposit
specimen
patient
includ
ten
specimen
eight
patient
recurr
hrv
infect
followup
period
fiftyeight
patient
hrva
hrvb
hrvc
infect
one
identifi
patient
urti
sign
symptom
sever
respiratori
ill
similar
across
hrv
speci
tabl
univari
analysi
differ
rate
lrti
among
patient
hrvc
versu
hrvahrvb
infect
among
patient
proven
hrv
lrti
hrv
type
determin
bal
fluid
specimen
yield
nine
distinct
hrva
one
hrvc
fiftyon
differ
hrv
type
determin
sequenc
analysi
includ
hrva
five
hrvb
hrvc
common
circul
type
detect
five
patient
phylogenet
analysi
gene
region
amplifi
cdc
unpublish
primer
perform
sequenc
bs
fig
eight
hrvc
fig
hrv
infect
peak
fall
winter
fig
hrva
infect
occur
yearround
peak
late
spring
fall
hrvb
hrvc
infect
cluster
late
fall
winter
month
among
patient
hrv
urti
patient
symptomat
resolut
infect
four
patient
develop
sign
symptom
lrti
within
day
includ
two
case
bronchiol
respiratori
copathogen
detect
sputum
bal
fluid
latter
avail
two
case
one
patient
lost
followup
overal
surviv
among
patient
hrv
lrti
overal
mortal
patient
die
respiratori
caus
compar
patient
possibl
hrv
lrti
patient
proven
hrv
lrti
like
requir
oxygen
supplement
mechan
ventil
intens
care
unit
admiss
data
shown
overal
mortal
similar
group
death
due
respiratori
caus
common
patient
proven
hrv
lrti
p
episod
recurr
hrvassoci
respiratori
ill
among
patient
six
month
follow
initi
hrv
infect
hrv
type
determin
recurr
ill
episod
median
time
episod
day
rang
day
molecular
type
given
patient
detect
six
episod
differ
type
detect
four
episod
period
hm
patient
diagnos
hrv
infect
nypwcmc
knowledg
largest
studi
clinic
molecular
epidemiolog
hrv
among
hm
patient
major
patient
hrv
urti
substanti
minor
lrti
case
mild
hrv
urti
may
miss
clinician
pursu
diagnost
test
one
infer
absolut
frequenc
lrti
among
patient
hrv
urti
progress
lrti
within
day
suggest
symptomat
hrv
lrti
rel
uncommon
among
hm
patient
hrv
infect
observ
rate
studi
stem
greater
tendenc
seek
medic
care
one
ill
nevertheless
patient
proven
hrv
lrti
ill
sever
consider
nearli
requir
icu
monitor
rel
role
viru
host
immun
respons
hrv
pathogen
subject
debat
perhap
even
complex
among
hm
patient
innat
adapt
immun
dysregul
due
underli
diseas
chemotherapi
hypoalbuminemia
independ
associ
hrv
lrti
like
mark
catabol
state
due
infect
possibl
malnutrit
routin
clinic
laboratori
marker
immunosuppress
similar
hrv
urti
lrti
case
prospect
measur
cytokin
chemokin
nasal
lavag
bal
fluid
hrvinfect
hm
patient
anoth
mean
understand
hrv
pathogen
immunocompromis
host
detect
bacteri
copathogen
occur
patient
hrv
lrti
observ
support
vitro
data
hrv
increas
suscept
bacteri
infect
upper
lower
respiratori
epithelium
pathogen
includ
staphylococcu
aureu
streptococcu
pneumonia
impair
cytokin
respons
hrvactiv
alveolar
macrophag
unfortun
due
low
number
case
studi
studi
immunocompromis
host
unabl
compar
risk
factor
outcom
hm
patient
hrv
lrti
without
copathogen
phylogenet
analysi
illustr
remark
divers
hrv
type
circul
greater
nyc
area
monthperiod
fiftyon
hrv
type
one
ev
identifi
suggest
communityacquisit
infect
cohort
immunocompromis
patient
among
patient
infect
hrv
type
readili
identifi
risk
factor
healthcareassoci
transmiss
observ
follow
lrti
rate
across
hrv
speci
hrva
hrvb
hrvc
studi
patient
popul
fail
associ
hrv
speci
lrti
compar
hrva
hrvc
hrvb
often
omit
analys
due
rel
low
preval
consist
observ
trend
hrvb
less
frequent
associ
lrti
nakagom
et
al
demonstr
hrvb
lower
slower
replic
cultur
sinu
epitheli
cell
well
lower
cytokin
chemokin
product
compar
hrva
hrvc
prolong
shed
hrv
welldescrib
immunocompromis
host
studi
design
assess
microbiolog
resolut
infect
among
episod
clinic
distinct
hrv
infect
occur
initi
episod
hrv
type
identifi
six
episod
hypothes
recurr
symptom
may
due
viral
reactiv
host
immun
fluctuat
convers
acquisit
new
hrv
type
four
patient
recurr
urti
suggest
role
improv
prevent
measur
includ
social
distanc
respiratori
mask
hand
hygien
studi
sever
limit
first
microbiolog
data
captur
singl
time
point
could
confirm
hrv
infect
preced
therefor
predispos
case
bacteri
coinfect
second
among
patient
differ
hm
consider
heterogen
host
immun
due
underli
diseas
chemotherapi
may
confound
abil
isol
host
factor
associ
hrv
lrti
possibl
frequenc
hrv
underestim
cohort
given
pcr
assay
abl
detect
known
hrv
twenti
respiratori
specimen
molecularli
type
usual
due
low
viral
load
addit
despit
use
highli
degener
primer
extens
sequenc
variabl
region
target
make
univers
type
hrv
challeng
conclus
hrv
associ
sever
lrti
hm
patient
yet
clinic
spectrum
infect
attribut
specif
hrv
speci
type
addit
studi
need
assess
viral
host
characterist
influenc
hrv
ill
sever
transmiss
among
immunocompromis
patient
therebi
inform
antivir
vaccin
effort
none
work
support
nation
institut
allergi
infecti
diseas
nation
institut
health
grant
clinic
translat
scienc
center
weill
cornel
medic
colleg
grant
dr
walsh
scholar
sharp
famili
foundat
pediatr
infecti
diseas
scholar
emerg
infecti
diseas
save
sick
kid
foundat
studi
approv
institut
review
board
weill
cornel
medic
colleg
new
york
state
depart
health
